BK:NYSE

The stock is trading at $115.1, just below its 20‑day SMA of $118.95 and near the identified support level of $111.71. Momentum indicators are mixed, with an RSI of 41.6 (neutral) and a bearish MACD histogram of ‑0.46, while volume has been on a decreasing trend. The market’s fear‑greed index sits at 75.9, labeled “Extreme Greed,” suggesting bullish sentiment despite the technical softness. Recent material news includes a $500 million preferred‑stock offering (Series I, 6.25% fixed‑rate reset), which expands the firm’s long‑term funding base. Analysts collectively rate the stock as Buy, with a median price target of $136, implying roughly 16% upside from the current level. The 30‑day realized volatility is high at 31.8%, reflecting notable price swings. Overall, the equity shows a neutral trend direction but is positioned near its short‑term support.
On the valuation side, BK trades at a PE of 15.6, comfortably below the industry average of 17.4, and its forward PE of 12.3 points to earnings acceleration. The dividend yield of 1.84% with a modest 27% payout ratio indicates a sustainable dividend profile. With revenue growth of 7.8%, operating margin of 37.3%, and a robust cash pile of $188 billion, the fundamentals are solid. The DCF‑derived fair value of $286.6 suggests a long‑term undervaluation, though the more conservative analyst median target of $136 still provides a healthy upside. The company’s beta of roughly 0.92 and a low debt‑to‑equity position mitigate systematic and balance‑sheet risks. Consequently, the stock is viewed as undervalued with a blend growth/value profile, making it attractive for investors with a medium‑to‑long‑term horizon.